Will Functional Genomics Cure Big Pharma’s Failure Rate?

Drug discovery is a notoriously expensive and inefficient endeavor. Nine of 10 drug candidates that go through the cost-intensive, years-long clinical trial process never make it to market. That 90% failure rate–a drag on medical progress and a factor often cited by pharmaceutical companies to justify sky-high drug prices–has proven frustratingly sticky even in an […]

Novartis CEO: It’s Time to “Pivot Towards Transformational Innovation”

Vasant Narasimhan is bringing a unique brand of leadership to his job as CEO of Novartis (NVS). It’s not surprising when you hear about his unusual background and his path to the C-Suite. A Harvard-trained physician and former McKinsey & Company consultant, he worked for years in developing countries on a range of challenging public […]

Fewer People Are Strategizing With Prescription Drug Choices to Control Their Health Care Costs

The U.S. has the highest drug prices in the world. Despite enormous expenses in research and marketing, pharmaceutical companies have the tenth highest profit levels among all industries. Despite some attention from Congress and the administration, prices remain high and promise to continue do so, at least in the immediate future. You might expect that […]

U.S. Drug Prices, But Not Out-of-Pocket Costs, Are the World’s Highest

With drug prices rising sitting at 10% of skyrocketing health care costs and pharmaceutical companies socking away big profits, you might assume that the U.S. has the highest prescription drug spending in the world. And you’d be right. Per capita prescription expenses in 2016 were $1,016 in this country, while the comparable country average was […]

Trump Administration Hands Out Record Number of Orphan Drug Approvals

A federal incentive for research into rare diseases for so-called orphan drugs is beloved by pharmaceutical companies. And during Donald Trump’s first two years in office, the Food and Drug Administration has been authorizing them at an unprecedented rate, according to Axios. Rare diseases are those that affect 200,000 or fewer people in the country, […]

Drugmaker Lilly to Launch a Half-Price, Generic Version of Its Top-Selling Insulin

Drugmaker Eli Lilly & Co. will offer a half-priced version of its blockbuster insulin, becoming one of the first companies to effectively cut the price of a top-selling drug amid the ongoing U.S. debate over pharmaceutical costs. While it will continue selling its brand-name version at the existing price, Indianapolis-based Lilly will also sell a […]